menu
    • menu
    [{"orgOrder":0,"company":"Emtora Biosciences","sponsor":"Biodexa Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Emtora Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Emtora Biosciences \/ Biodexa Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Emtora Biosciences \/ Biodexa Pharmaceuticals"},{"orgOrder":0,"company":"Emtora Biosciences","sponsor":"Cancer Insight | Biodexa Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Emtora Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Emtora Biosciences \/ Cancer Insight | Biodexa Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Emtora Biosciences \/ Cancer Insight | Biodexa Pharmaceuticals"},{"orgOrder":0,"company":"Emtora Biosciences","sponsor":"CPRIT","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibiotic","year":"2025","type":"Funding","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Emtora Biosciences","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.02,"dosageForm":"Capsule","sponsorNew":"Emtora Biosciences \/ CPRIT","highestDevelopmentStatusID":"10","companyTruncated":"Emtora Biosciences \/ CPRIT"},{"orgOrder":0,"company":"Emtora Biosciences","sponsor":"Biodexa Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Licensing Agreement","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Emtora Biosciences","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.040000000000000001,"dosageForm":"Capsule","sponsorNew":"Emtora Biosciences \/ Biodexa Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Emtora Biosciences \/ Biodexa Pharmaceuticals"},{"orgOrder":0,"company":"Emtora Biosciences","sponsor":"Cancer Prevention and Research Institute of Texas","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Funding","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Emtora Biosciences","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.02,"dosageForm":"Capsule","sponsorNew":"Emtora Biosciences \/ Cancer Prevention and Research Institute of Texas","highestDevelopmentStatusID":"10","companyTruncated":"Emtora Biosciences \/ Cancer Prevention and Research Institute of Texas"},{"orgOrder":0,"company":"Emtora Biosciences","sponsor":"Cancer Insight","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2018","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Oncology","graph2":"Phase I","graph3":"Emtora Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Emtora Biosciences \/ Cancer Insight","highestDevelopmentStatusID":"6","companyTruncated":"Emtora Biosciences \/ Cancer Insight"},{"orgOrder":0,"company":"Emtora Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Oncology","graph2":"Phase I","graph3":"Emtora Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Emtora Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Emtora Biosciences \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Emtora Biosciences

    Menu

    Emtora Biosciences

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Emtora Biosciences

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Emtora Biosciences

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sirolimus

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase III

                            Sponsor : CPRIT

                            Deal Size : $20.0 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Biodexa Wins Extra $3M CPRIT Grant Bringing eRapa Phase 3 Total to $20M

                            Details : The funding will be used to support registrational eRapa, a proprietary oral tablet formulation of rapamycin, phase 3 program in familial adenomatous polyposis.

                            Product Name : eRapa

                            Product Type : Antibiotic

                            Upfront Cash : Undisclosed

                            May 22, 2025

                            Lead Product(s) : Sirolimus

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase III

                            Sponsor : CPRIT

                            Deal Size : $20.0 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Emtora Biosciences

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Emtora Biosciences

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sirolimus

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase III

                            Sponsor : Biodexa Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase 3 Trial of eRapa in Patients With Familial Adenomatous Polyposis

                            Details : ERapa (Rapamycin) is a Antibiotic drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Adenomatous Polyposis Coli.

                            Product Name : eRapa

                            Product Type : Antibiotic

                            Upfront Cash : Inapplicable

                            April 30, 2025

                            Lead Product(s) : Sirolimus

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase III

                            Sponsor : Biodexa Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Emtora Biosciences

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Emtora Biosciences

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sirolimus

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase II

                            Sponsor : Biodexa Pharmaceuticals

                            Deal Size : $41.5 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Biodexa Licenses eRapa™ for Familial Adenomatous Polyposis Treatment

                            Details : Under the agreement, Biodexa gains rights to develop and commercialize eRapa, a proprietary oral rapamycin formulation and mTOR inhibitor for the treatment of Familial Adenomatous Polyposis.

                            Product Name : eRapa

                            Product Type : Antibiotic

                            Upfront Cash : Undisclosed

                            April 26, 2024

                            Lead Product(s) : Sirolimus

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase II

                            Sponsor : Biodexa Pharmaceuticals

                            Deal Size : $41.5 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Emtora Biosciences

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Emtora Biosciences

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sirolimus

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase II

                            Sponsor : Cancer Prevention and Research Institute of Texas

                            Deal Size : $19.9 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Emtora Biosciences Receives $16.9M Grant from the Cancer Prevention & Research Institute of Texas

                            Details : Emtora plans to use the CPRIT award to complete a multicenter, randomized, placebo-controlled Phase 3 trial of eRapa (rapamycin) in patients with FAP. Patients with FAP are predisposed to the development of hundreds or even thousands of polyps in their g...

                            Product Name : eRapa

                            Product Type : Antibiotic

                            Upfront Cash : Undisclosed

                            August 19, 2022

                            Lead Product(s) : Sirolimus

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase II

                            Sponsor : Cancer Prevention and Research Institute of Texas

                            Deal Size : $19.9 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Emtora Biosciences

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Emtora Biosciences

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sirolimus

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Emtora Presents Phase Ib Data in Low Grade Prostate Cancer

                            Details : In patients with low-grade PCa, treatment with low dose eRapa was found to be safe and well-tolerated.

                            Product Name : eRapa

                            Product Type : Antibiotic

                            Upfront Cash : Inapplicable

                            February 04, 2020

                            Lead Product(s) : Sirolimus

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Emtora Biosciences

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Emtora Biosciences

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sirolimus

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase II

                            Sponsor : Cancer Insight | Biodexa Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Trial of ERapa to Prevent Progression in Familial Adenomatous Polyposis Patients Under Active Surveillance

                            Details : ERapa (Rapamycin) is a Antibiotic drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Adenomatous Polyposis Coli.

                            Product Name : eRapa

                            Product Type : Antibiotic

                            Upfront Cash : Inapplicable

                            January 18, 2020

                            Lead Product(s) : Sirolimus

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase II

                            Sponsor : Cancer Insight | Biodexa Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Emtora Biosciences

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Emtora Biosciences

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sirolimus

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Cancer Insight

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Trial of eRapa in Prostate Cancer Patients

                            Details : ERapa (Rapamycin) is a Antibiotic drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Prostatic Neoplasms.

                            Product Name : eRapa

                            Product Type : Antibiotic

                            Upfront Cash : Inapplicable

                            August 07, 2018

                            Lead Product(s) : Sirolimus

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Cancer Insight

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth